These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 32444995)

  • 41. Lansoprazole alleviates pressure overload-induced cardiac hypertrophy and heart failure in mice by blocking the activation of β-catenin.
    Lin H; Li Y; Zhu H; Wang Q; Chen Z; Chen L; Zhu Y; Zheng C; Wang Y; Liao W; Bin J; Kitakaze M; Liao Y
    Cardiovasc Res; 2020 Jan; 116(1):101-113. PubMed ID: 30689763
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chronically Elevating Circulating Ketones Can Reduce Cardiac Inflammation and Blunt the Development of Heart Failure.
    Byrne NJ; Soni S; Takahara S; Ferdaoussi M; Al Batran R; Darwesh AM; Levasseur JL; Beker D; Vos DY; Schmidt MA; Alam AS; Maayah ZH; Schertzer JD; Seubert JM; Ussher JR; Dyck JRB
    Circ Heart Fail; 2020 Jun; 13(6):e006573. PubMed ID: 32493060
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF.
    Schauer A; Adams V; Augstein A; Jannasch A; Draskowski R; Kirchhoff V; Goto K; Mittag J; Galli R; Männel A; Barthel P; Linke A; Winzer EB
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808232
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation.
    Kang DH; Park SJ; Shin SH; Hong GR; Lee S; Kim MS; Yun SC; Song JM; Park SW; Kim JJ
    Circulation; 2019 Mar; 139(11):1354-1365. PubMed ID: 30586756
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Myocardial reverse remodeling after pressure unloading is associated with maintained cardiac mechanoenergetics in a rat model of left ventricular hypertrophy.
    Ruppert M; Korkmaz-Icöz S; Li S; Németh BT; Hegedűs P; Brlecic P; Mátyás C; Zorn M; Merkely B; Karck M; Radovits T; Szabó G
    Am J Physiol Heart Circ Physiol; 2016 Sep; 311(3):H592-603. PubMed ID: 27342874
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
    Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
    Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Toll-like receptor-2 mediates adaptive cardiac hypertrophy in response to pressure overload through interleukin-1β upregulation via nuclear factor κB activation.
    Higashikuni Y; Tanaka K; Kato M; Nureki O; Hirata Y; Nagai R; Komuro I; Sata M
    J Am Heart Assoc; 2013 Nov; 2(6):e000267. PubMed ID: 24249711
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The SGK1 inhibitor EMD638683, prevents Angiotensin II-induced cardiac inflammation and fibrosis by blocking NLRP3 inflammasome activation.
    Gan W; Ren J; Li T; Lv S; Li C; Liu Z; Yang M
    Biochim Biophys Acta Mol Basis Dis; 2018 Jan; 1864(1):1-10. PubMed ID: 28986310
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Olmesartan attenuates cardiac remodeling through DLL4/Notch1 pathway activation in pressure overload mice.
    You J; Wu J; Jiang G; Guo J; Wang S; Li L; Ge J; Zou Y
    J Cardiovasc Pharmacol; 2013 Feb; 61(2):142-51. PubMed ID: 23188126
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synergy between sacubitril and valsartan leads to hemodynamic, antifibrotic, and exercise tolerance benefits in rats with preexisting heart failure.
    Maslov MY; Foianini S; Mayer D; Orlov MV; Lovich MA
    Am J Physiol Heart Circ Physiol; 2019 Feb; 316(2):H289-H297. PubMed ID: 30461302
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sacubitril/Valsartan Inhibits Cardiomyocyte Hypertrophy in Angiotensin II-Induced Hypertensive Mice Independent of a Blood Pressure-Lowering Effect.
    Tashiro K; Kuwano T; Ideishi A; Morita H; Idemoto Y; Goto M; Suematsu Y; Miura SI
    Cardiol Res; 2020 Dec; 11(6):376-385. PubMed ID: 33224383
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sacubitril and valsartan protect from experimental myocardial infarction by ameliorating oxidative damage in Wistar rats.
    Imran M; Hassan MQ; Akhtar MS; Rahman O; Akhtar M; Najmi AK
    Clin Exp Hypertens; 2019; 41(1):62-69. PubMed ID: 29595329
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sacubitril/valsartan attenuates myocardial inflammation, hypertrophy, and fibrosis in rats with heart failure with preserved ejection fraction.
    Shi YJ; Yang CG; Qiao WB; Liu YC; Liu SY; Dong GJ
    Eur J Pharmacol; 2023 Dec; 961():176170. PubMed ID: 37939991
    [TBL] [Abstract][Full Text] [Related]  

  • 54. NLRP3 Inflammasome Promotes Myocardial Remodeling During Diet-Induced Obesity.
    Sokolova M; Sjaastad I; Louwe MC; Alfsnes K; Aronsen JM; Zhang L; Haugstad SB; Bendiksen BA; Øgaard J; Bliksøen M; Lien E; Berge RK; Aukrust P; Ranheim T; Yndestad A
    Front Immunol; 2019; 10():1621. PubMed ID: 31379826
    [No Abstract]   [Full Text] [Related]  

  • 55. Semaglutide ameliorates pressure overload-induced cardiac hypertrophy by improving cardiac mitophagy to suppress the activation of NLRP3 inflammasome.
    He W; Wei J; Liu X; Zhang Z; Huang R; Jiang Z
    Sci Rep; 2024 May; 14(1):11824. PubMed ID: 38782946
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sacubitril/valsartan attenuates myocardial ischemia/reperfusion injury via inhibition of the GSK3β/NF-κB pathway in cardiomyocytes.
    Xiao F; Wang L; Liu M; Chen M; He H; Jia Z; Zhang L; Yang Y; Hu Q; Hong M; Zhang H
    Arch Biochem Biophys; 2022 Nov; 730():109415. PubMed ID: 36179911
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sacubitril/valsartan improves medium-term reverse left ventricular remodeling: why wait?
    Santangelo G; Bursi F; Toriello F; Valli F; Tombolini E; Torta D; Bosotti L; Massironi L; Carugo S
    J Cardiovasc Med (Hagerstown); 2019 Oct; 20(10):727-729. PubMed ID: 31169634
    [No Abstract]   [Full Text] [Related]  

  • 58. Effects of the TLR4/Myd88/NF-κB Signaling Pathway on NLRP3 Inflammasome in Coronary Microembolization-Induced Myocardial Injury.
    Su Q; Li L; Sun Y; Yang H; Ye Z; Zhao J
    Cell Physiol Biochem; 2018; 47(4):1497-1508. PubMed ID: 29940584
    [TBL] [Abstract][Full Text] [Related]  

  • 59. LCZ696 (sacubitril/valsartan) protects against cyclophosphamide-induced testicular toxicity in rats: Role of neprilysin inhibition and lncRNA TUG1 in ameliorating apoptosis.
    Salama RM; Abd Elwahab AH; Abd-Elgalil MM; Elmongy NF; Schaalan MF
    Toxicology; 2020 May; 437():152439. PubMed ID: 32197949
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Angiotensin II receptor blocker reduces oxidative stress and attenuates hypoxia-induced left ventricular remodeling in apolipoprotein E-knockout mice.
    Yamashita C; Hayashi T; Mori T; Tazawa N; Kwak CJ; Nakano D; Sohmiya K; Okada Y; Kitaura Y; Matsumura Y
    Hypertens Res; 2007 Dec; 30(12):1219-30. PubMed ID: 18344628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.